fbpx

Day: August 12, 2020

California’s political leaders are pushing rideshare companies and consumers will suffer

fe0c9ad558c9408a9c8aa776e285a307.png

San Francisco, CA – On Wednesday, the CEO of Uber said that if California’s AB5 law is carried out against rideshare firms, the company will consider pulling all of its services from the state.

Yaël Ossowski, deputy director of the Consumer Choice Center, a consumer advocacy group, calls it a “sad day” for California rideshare consumers drivers.

“Through AB5 and similar legislation, California’s politicians have been sending the signal that rideshare companies are not welcome in the Golden State. But that’s not what consumers want,” said Ossowski. “The flexible model that has so far propelled the growth of companies like Uber, Lyft, and others has been beneficial for both drivers who want independence and consumers who want convenience and competitive prices.

“If Uber and other companies shut down in California, it will prove that the state is no longer a hotbed of innovation, but rather the place where innovation goes to die. It’s unfortunate that millions of Californians will be deprived of more choice if that happens. The same has also proven true for the thousands of freelancers who now find themselves out of work.

“California politicians may have the noblest of intentions, but forcing rideshare companies to become taxi companies does nothing but help the taxi cartel maintain its monopoly and deprive people of earning a living on their own terms.

“Hopefully, voters will choose to support Prop 22 in the fall to reverse course and restore the ability of drivers and other freelancers to earn a living how they want,” said Ossowski.

##

The Consumer Choice Center represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva, and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org.

CONTACT:

Yaël Ossowski

Deputy Director

Consumer Choice Center

yael@consumerchoicecenter.org

Think of the children! How to find cures for rare and children diseases.

The European Commission just published a working document assessing the EU’s orphan and pediatric drug strategies. Read here why incentives for research are key to extending patients’ lives:

A rare disease is a medical condition that meets the criteria defined in Article 3 of Regulation (EC) No 141/2000; a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 persons in the EU. Although so-called rare diseases affect a limited number of people per disease, collectively they affect one person in every 17 people within Europe. There are over 7,000 different rare diseases patients suffer from.

Regulators see an ‘imbalance of risk and reward’ for the industry to find cures and treatments for those diseases. Hence US, Japanese and EU regulators increased options for longer market exclusivity for drugs tackling diseases in children and rare diseases. In 2000, Regulation (EC) No 141/2000 and  2006 Regulation (EC) No 1901/2006 were adopted by the European Commission. The ‘standard’ incentives provided by the general legislative framework for pharmaceuticals in the EU are 10 years of market protection and 20 years of patent protection. For pediatric and orphan drugs manufacturers can apply for extended market exclusivity.

The purpose of this strategy is to improve and expedite patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. Adding prolonged exclusivity worked: A massive increase in orphan drugs could be seen in the last 20 years! Between 2012 and 2017 over three times as many orphan drugs entered the EU compared to 2000-2005. The EU Commission estimated that between 200,000 and 440,000 additional quality-adjusted life years were gained thanks to more incentives for these drugs.

Added IP Protection for Orphan Drugs correlates with more drugs entering the market

Voices who call now for less protection of orphan and pediatric drugs want to undo the successes of the last two decades. The 142 orphan medicines authorized between 2000 and 2017 have helped up to 6.3 million patients in the EU to either cure or cope with their health conditions.

But there are still millions of patients waiting for a breakthrough that can help to treat their rare or pediatric disease – For this, we need to have incentives and not populism. Intellectual property is key in allowing the inventor and her investors to reward them for their massive risk they undertook in trying to find a cure or treatment for a rare disease. The EU’s approach to orphan and pediatric drugs by increasing incentives for inventors and manufacturers has worked. The successes of the past 20 years should not be undermined by populist calls to nationalize research and IP. If we care about patients with rare diseases, we should not question the importance of protecting intellectual property but see it as a precondition for future innovations.

To sum it up: Think of the children and allow medical innovation to take place!

Consumer Choice Center Joins Coalition Opposed To Most Favored Nation Drug Pricing Proposal

Dear President Trump:

On behalf of the undersigned federal and state-based organizations, we write to express our grave concerns with the “most favored nation” (MFN) executive order to impose foreign price controls on American medicines.

This proposal will impose an “International Pricing Index” on drugs in Medicare Part B, tying the U.S. prices for these medicines to the prices in foreign countries, most of which have government-set prices established in socialized medicine systems.

Adopting these price controls will slow medical innovation, threaten American jobs, and undermine criticism of single-payer systems. In addition, a United States embrace of price controls will make it immeasurably more difficult to get foreign countries to pay their own way in the development of new medicines.

Your administration has repeatedly stood strong against a government-takeover of healthcare. In fact, in your 2020 State of the Union Address, you promised that “we will never let socialism destroy American health care.”

We applaud your strong stance – socialized healthcare policies proposed by some leading presidential candidates would require trillions of dollars in tax increases, would destroy medical progress, and would end healthcare plans used by 180 million Americans.

Unfortunately, an MFN policy would adopt the same socialist healthcare policies that you have promised to fight against.

Not only does this undermine the broader effort to fight against the government takeover of health care, it will also have disastrous consequences to the economy and healthcare system.

The U.S. is the best in the world when it comes to developing innovative, lifesaving and life preserving medicines. Because of this, the U.S. is leading the way when it comes to developing COVID-19 vaccines, with several promising candidates entering the final stages of testing and clinical trials.

In contrast, foreign countries have been free riding off this American medical innovation for decades through crushing price controls and other market-distorting government rules and regulations.

Adopting foreign price controls will result in the same negative outcomes to our healthcare system as those overseas—less medical innovation leading to fewer cures and healthcare shortages for American patients.

Adopting price controls through an MFN will also harm the U.S. economy because of a decline in American research and development. Medical innovation directly or indirectly supports 4 million jobs and $1.1 trillion in total economic impact, which will be threatened by importing price controls.

An MFN does nothing to fight foreign free riding of American innovation. Although supporters of MFN have claimed the concept will incentivize manufacturers to negotiate better deals, this theory is based on the flawed assumption that American manufacturers were not fighting as hard as they could against foreign price controls in past years. In addition, an American adoption of these same policies renders any future criticism of them incredibly challenging.

Moving forward, we need policies that further encourage American innovation through tax and trade policies, such as renegotiated trade deals, a competitive business tax system and a more competitive environment.

As President, you have championed vital changes in tax and regulatory policies that have allowed free market innovation to flourish. We believe a market-based approach like those that your administration has consistently supported in other policy areas will lead to economic growth and promising new treatments but adopting price controls through the MFN plan would undermine rather than build on those successes. In short, if the MFN executive order is implemented it will have disastrous consequences for both American healthcare and the American economy.

Sincerely,

Grover Norquist
President, Americans for Tax Reform

Saulius “Saul” Anuzis
President, 60 Plus Association

Jim Martin
Founder/Chairman, 60 Plus
Association

Marty Connors
Leader, Alabama Center-Right
Coalition

Bethany Marcum
Executive Director, Alaska Policy
Forum

Phil Kerpen
President, American Commitment

Daniel Schneider
Executive Director, American
Conservative Union

Dee Stewart
President, Americans for a
Balanced Budget

Richard Manning
President, Americans for Limited
Government

Brent Wm. Gardner
Chief Government Affairs Officer,
Americans for Prosperity

Lisa B. Nelson
CEO, ALEC

Michael Bowman
President, ALEC Action

Kevin Waterman
Chair, Annapolis Center-Right
Coalition Meeting (Maryland)

Robert Alt
President and CEO, The Buckeye Institute

Rabbi Aryeh Spero
President, Caucus for America

Ryan Ellis
President, Center for a Free Economy

Andrew F. Quinlan
President, Center for Freedom and Prosperity

Jeffrey Mazzella
President, Center for Individual Freedom

Ginevra Joyce-Myers
Executive Director, Center for Innovation and Free Enterprise

Peter Pitts
President, Center for Medicine in the Public Interest

John Hinderaker
President, Center of the American Experiment

Thomas Schatz
President, Citizens Against Government Waste

Leo Knepper
CEO, Citizens Alliance of Pennsylvania

Donald Bryson
President & CEO, Civitas Institute

Regina Thomson
President, Colorado Issues Coalition

Gregory Conko
Senior Fellow, Competitive Enterprise Institute

James Edwards
Executive Director, Conservatives for Property Rights

Matthew Kandrach
President, Consumer Action for a Strong Economy

Fred Roeder
Health Economist/Managing Director, Consumer Choice Center

Yaël Ossowski
Deputy Director, Consumer Choice Center

Joel White
President, Council for Affordable Health Coverage

Katie McAuliffe
Executive Director, Digital Liberty

Robert Roper
President, Ethan Allen Institute

Adam Brandon
President, FreedomWorks

Annette Meeks
CEO, Freedom Foundation of Minnesota

George Landrith
President, Frontiers of Freedom

Grace Marie-Turner
President, Galen Institute
(organization listed for affiliation purposes only)

Ray Chadwick,
Chairman, Granite State Taxpayers

Naomi Lopez
Director of Healthcare Policy, Goldwater Institute

Mario H. Lopez
President, Hispanic Leadership Fund

Carrie Lukas
President, Independent Women’s Forum

Heather R. Higgins
CEO, Independent Women’s Voice

Andrew Langer
President, Institute for Liberty

Tom Giovanetti
President, Institute for Policy Innovation

Sal Nuzzo
Vice President of Policy, James Madison Institute

Amy Oliver Cooke
CEO, John Locke Foundation

Drew Cline
President, Josiah Bartlett Center for Public Policy

Seton Motley
President, Less Government

Jay Fisher
Immediate Past Chairman, Lisle Township Republican Organization

Doug McCullough
Director, Lone Star Policy Institute

Lindsay Killen
Vice President for Strategic Outreach, Mackinac Center for Public Policy

Brett Healy
President, The John K. MacIver Institute for Public Policy

Matt Gagnon
President, Maine Policy Institute

Charles Sauer
President, Market Institute

Dee Hodges
President, Maryland Taxpayers Association, Inc

Gene Clem
Spokesman, Michigan Tea Party Alliance

Jameson Taylor, Ph.D.
Vice President for Policy, Mississippi Center for Public Policy

Tim Jones
Chair, Missouri Center-Right Coalition
Fmr. Speaker, Missouri House

David A. Ridenour
President, National Center for Public Policy Research

Everett Wilkinson
Chairman, National Liberty Federation

Pete Sepp
President, National Taxpayers Union

John Tsarpalas
President, Nevada Policy Research Institute

Scott Pullins
Founder, Ohio Taxpayers Association

Doug Kellogg
Executive Director, Ohioans for Tax Reform

Sally Pipes
President and CEO, Pacific Research Institute

Ellen Weaver
President & CEO, Palmetto Promise Institute

Daniel Erspamer
Chief Executive Officer, Pelican Institute for Public Policy

Ed Martin
President, Phyllis Schlafly Eagles

Lorenzo Montanari
Executive Director, Property Rights Alliance

Stone Washington
Member, Project 21

Paul J. Gessing
President, Rio Grande Foundation

Bette Grande
President & CEO, Roughrider Policy Center

James L. Setterlund
Executive Director, Shareholder Advocacy Forum

Karen Kerrigan
President & CEO, Small Business & Entrepreneurship Council

Paul E. Vallely, Major General, US Army (ret)
Chairman, Stand Up America US Foundation

Richard Watson
Chair, Tallahassee Center-Right Coalition

David Williams
President, Taxpayers Protection Alliance

Sara Croom
Executive Director, Trade Alliance to Promote Prosperity

C. Preston Noell III
President, Tradition, Family, Property, Inc.

Lynn Taylor
President, Virginia Institute for Public Policy

Scroll to top
en_USEN